+

WO1993021953A1 - Composition for prophylaxis and treatment of pulmonary fibrosis - Google Patents

Composition for prophylaxis and treatment of pulmonary fibrosis Download PDF

Info

Publication number
WO1993021953A1
WO1993021953A1 PCT/GB1993/000886 GB9300886W WO9321953A1 WO 1993021953 A1 WO1993021953 A1 WO 1993021953A1 GB 9300886 W GB9300886 W GB 9300886W WO 9321953 A1 WO9321953 A1 WO 9321953A1
Authority
WO
WIPO (PCT)
Prior art keywords
pulmonary fibrosis
bleomycin
silica
treatment
lung
Prior art date
Application number
PCT/GB1993/000886
Other languages
French (fr)
Inventor
Pierre François PIGUET
Original Assignee
Whaley, Kevin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whaley, Kevin filed Critical Whaley, Kevin
Publication of WO1993021953A1 publication Critical patent/WO1993021953A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to a method of prophylaxis and treatment of pulmonary fibrosis. Furthermore, it relates to a pharmaceutical composition for the prophylaxis and treatment of pulmonary fibrosis. More generally it relates to the facilitation of wound repair- Pulmonary fibrosis is any one of a group of diseases characterised by an increase in the deposition of proteins of the extra-cellular matrix (ECM), notably collagens, generally associated with the growth of interstitial cells. These diseases respond poorly to current therapy, ⁇ and are responsible for about 5% of annual deaths in the USA (see Bitter an and Hen e in Chest, 1991, 99, 81s).
  • ECM extra-cellular matrix
  • cytokines have been characterized recently which might be involved in pulmonary fibrosis, notably tumor necrosis factor- ⁇ (TNF- ⁇ ), interleukin-1 ' (IL-1), transforming growth factor (TGF- ⁇ ) or platelet derived growth factor (PDGF) (see E. J. ova ⁇ s, Immunology Today, 1991, _12_, 17). Macrophages are known to produce several of these factors.
  • the lung contains various leukocytes (i. e. lymphocytes, macrophages and polynuclear leukocytes), in three distinct compartments - alveolar, interstitial and intra-vascular (see Abraham et al, J. Immunol. , 1990, 144, 2117), which may also play some role in the development of pulmonary fibrosis instead of normal healing of lesions.
  • pulmonary fibrosis The two most commonly used experimental models in the study of pulmonary fibrosis are the pulmonary fibrosis elicited by the instillation of either bleo ycin or silica (see D. H. Bowden, Laboratory I vestigation, 1984, 50, 487, and E. M. Lugano et al, Am. J. Pathol. , 1982, 109, 27). It has been shown that development of bleomycin-induced pulmonary fibrosis can be prevented by a depletion of T lymphocytes (Piguet et al, J. Exp. Med. , 1989, 170, 655), the presence of T-lymphocytes being necessary for both increased lung TNF RNA levels and the development of " fibrosis.
  • Sili ⁇ osis has been shown not to be markedly affected by the absence of T-lymphocytes. .It has also been shown that administration of anti-TNF antibodies to mice during instillation of silica almost completetly prevents deposition of collagen due to silica-induced pulmonary fibrosis (P. F. Piguet et al, Nature, 1990, 344, 245). Administration of anti-TNF antibdies, however, is much less effective in the prevention of pulmonary fibrosis induced by bleomycin (P. F. Piguet et al, J. Exp. Med. , 1989, 170, 655). Thus, although much research interest has centered on the possible development of the work with T-lympho ⁇ ytes and anti-TNF antibodies, it has become clear that neither approach is likely to provide a viable method of treatment of the complete range of pulmonary fibrosis.
  • a pharmaceutical composition is sought that may be' administered both as a means of preventing the onset of pulmonary fibrosis, and treating the condition after its onset.
  • the leukocytes of the lung may have some role to play in the evolution of pulmonary fibrosis.
  • the interactions and state of activation of leukocytes is known to be modulated by various surface proteins.
  • One such class of surface proteins is the leukocytic integrins.
  • leukocytic integrins There are " three leukocytic integrins, all of which are non-covalently linked heterodimers sharing a common ⁇ -subunit (CD-18) and different but homologous a-subunits: the CD-lla (or the LFA-1), the CD-lib (or Mac-1 or C 3), and the CD-llc (or the pl50, 95) (see Anderson and Springer in Ann. Rev. Med. , 1987, 38, 175).
  • the CD-ll/CD-18 family also known as the leukocytic or ⁇ -2 integrins, are believed to be involved in various immune and inflammatory responses on the basis of two pieces of evidence.
  • CD-18 congenital deficiencies in humans lead to a severe disease, known as Leukocyte Adhesion Deficiency (LAD), which is characterised by recurrent bacterial infections, and impaired pus formation and wound healing (see Anderson and Springer in Ann. Rev. Med., 1987, 3J3, 175).
  • LAD can be treated by bone marrow transplantation, donor rejection of HLA-mismatched bone marrow being overcome by administration of anti CD-lla mAbs to the patient from about 3 to 5 days before the graft.
  • pulmonary fibrosis may be elicited by the intratracheal instillation of bleomycin or silica in mice, significant increases in the lung hydroxyproline content being observed after 15 days.
  • simultaneous administration of either or both of anti CD-lla or anti CD-lib mAb during the period of instillation has been found to prevent excessive lung collagen deposition for both bleomycin and silica instillation, i. e. administration of the antibodies completely prevents the onset of both bleomycin and silica induced pulmonary fibrosis.
  • collagen levels in the lung are slightly lower after administration of anti CD-11 mAbs following the instillation of silica or bleomycin, than those in normal lungs in which no fibrosis have been elicited.
  • pulmonary fibrosis including idiopathi ⁇ pulmonary fibrosis, drug-induced pulmonary fibrosis, silicosis, pneumoconiosis (e.g. asbestosis, berylliosis), and acute respiratory distress syndrome (ARDS).
  • a monoclonal antibody to either or both of the leukocytic a sub-units CD-lla and CD-Ilb for the manufacture of a composition for the prophylaxis and treatment of pulmonary fibrosis in mammals.
  • the invention may be further illustrated by consideration of the Examples below.
  • the animals, materials and methods used in the Examples are as follows:
  • mice CBA/Ca and C57BL/10 (BIO) mice were purchased from OLAC Ltd. (Blackthorn, UK), and bred for 3-4 generations. Experiments were performed with 2-4 month old male mice.
  • Bleomycin (Lundbeck, AVA, Copenhagen, Denmark) was dissolved in HBSS and 0.08 U in 0.1 ml was injected intra-tracheally. This procedure induced some morbidity, manifested by a loss in body weight and death by the 15th day after the injection in 5-20% of the mice. About 2 mg silica particles (DQ 12, size ⁇ 5 micron) were suspended in 0.1 ml of saline, and injected intra-tracheally. This treatment did not induce detectable loss of body weight or mortality.
  • the alveolae were lavaged with saline instilled within the trachea by a 25 cm hydrostatic pressure.
  • Lung interstitial cells were isolated as described by Abraham et al, J. Immunol. , 1990, 144, 2117.
  • the lungs were fixed by the intra-tracheal administration of formol sublimate or glutaraldehyde (2% in 0.1M cacodylate buffer, pH 7.4) for paraffin or methacrylate and epon embedding respectively.
  • Four sections from paraffin embedded material for each individual mouse were stained with hematoxilin and eosin, and a modified trichrome stain was used for the identification of platelet aggregates.
  • RNAs denatured with glyoxal, were separated on 1.2% agarose gels (4 ⁇ g per lane), and transferred onto nylon membranes. . Filters were hybridised with 32P-labelled cRNA probes (see Collart et al, J. Exp. Med., 1986, 163, 2113).
  • Example 1
  • Pulmonary fibrosis were elicited in groups of mice by the instillation of bleomycin or silica as decribed above.
  • 500 ⁇ g of the anti CD-lla or anti CD-Ilb mAbs were injected every 5 days after instillation, and the mice were sacrificed on the 15th day after instillation.
  • Control tests were run in which saline was injected intra-tracheally at the beginning of the experiment, and in which saline was injected into the mice at 5 day intervals instead of the antibodies after instillation by bleomycin or silica.
  • Cells from the broncho-alveolar lavage (BAL) were recovered after an intra-tracheal instillation of saline.
  • the lung hydroxyproline as an evaluation of the lung collagen, was determined after lung hydrolysis. The results were as shown in Table 1 below.
  • silica saline 18 (4) 144 (48) silica anti CD-lla 10 (4) 89 (30)* silica anti CD-lib 16 (3) 80 (39)*
  • Results are the mean (+sd) of the values obtained with 7-10 mice.
  • the significance of the difference with the saline treated group was evaluated by the Mann and ithney non-parametric U test; *p ⁇ 0.02, **p ⁇ 10 -2
  • Pulmonary fibrosis was elicited in mice using bleomycin or silica as in Example 1.
  • Anti CD-lla mAbs 500 ⁇ g were administered to the mice on day 20 and day 25 and the mice were sacrificed on day 30 after silica or bleomycin instillation.
  • Control tests were run in which saline was injected at days 20 and 25 after instillation with silica or bleomycin instead of the mAbs. Mice, to which nothing had been administered throughout the period of the tests, were also sacrificed after 30 days. The results were as shown below in Table II. Table II
  • silica saline 120 (22 ) silica anti CD-lla 63 ( 10 ) *
  • Results are the mean (_+sd) of groups of 5 mice. Difference with the saline injected group; *p ⁇ 10 -3
  • the lung hydroxyproline content is approximately the same as the value for mice in which no fibrosis have been elicited, while in the case of silica induced fibrosis, the lung hydroxyproline content is actually below that of the value obtained for mice in which no fibrosis have been elicited.
  • Pulmonary fibrosis was elicited using silica or bleomycin in groups of 4-8 mice as described in Example 1. On day 15 the lungs were fixed by an intra-tracheal instillation of formol sublimate, and 3-4 sections across the hilus of the major lobes were prepared for each individual mouse. Sections were scored semi-quantitatively as follows:
  • Lymphoid infiltration was evaluated as the number of lymphoid foci (i.e. lymphoid formation of >20) per section.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A monoclonal antibody to either or both of the leukocytic α sub-units CD-11a and CD-11b is used for the manufacture of a composition for the prophylaxis and treatment of pulmonary fibrosis in mammals. A method of prophylaxis and treatment of pulmonary fibrosis in mammals by the administration of an effective amount of a monoclonal antibody to either or both of the leukocytic α sub-units CD-11a and CD-11b is also provided.

Description

COMPOSITION FOR PROPHYLAXIS AND TREATMENT OF PULMONARY FIBROSIS
The invention relates to a method of prophylaxis and treatment of pulmonary fibrosis. Furthermore, it relates to a pharmaceutical composition for the prophylaxis and treatment of pulmonary fibrosis. More generally it relates to the facilitation of wound repair- Pulmonary fibrosis is any one of a group of diseases characterised by an increase in the deposition of proteins of the extra-cellular matrix (ECM), notably collagens, generally associated with the growth of interstitial cells. These diseases respond poorly to current therapy, ~and are responsible for about 5% of annual deaths in the USA (see Bitter an and Hen e in Chest, 1991, 99, 81s). The onset of pulmonary fibrosis is frequently associated with tissue injury which results in parenchymal death, leading to a complex pattern of responses being engaged which should lead to organ repair. However, under certain circumstances, instead of repair being initiated, a fibroproliferative response may ensue, in which parenchyma is replaced by esenchymal cells, new capillaries, and their connective tissue products. The reason why injury sometimes leads to complete repair, while other times it results in fibrosis is as yet poorly understood. Several fibrogenic cytokines have been characterized recently which might be involved in pulmonary fibrosis, notably tumor necrosis factor-α (TNF-α), interleukin-1' (IL-1), transforming growth factor (TGF-β) or platelet derived growth factor (PDGF) (see E. J. ovaσs, Immunology Today, 1991, _12_, 17). Macrophages are known to produce several of these factors. The lung contains various leukocytes (i. e. lymphocytes, macrophages and polynuclear leukocytes), in three distinct compartments - alveolar, interstitial and intra-vascular (see Abraham et al, J. Immunol. , 1990, 144, 2117), which may also play some role in the development of pulmonary fibrosis instead of normal healing of lesions.
The two most commonly used experimental models in the study of pulmonary fibrosis are the pulmonary fibrosis elicited by the instillation of either bleo ycin or silica (see D. H. Bowden, Laboratory I vestigation, 1984, 50, 487, and E. M. Lugano et al, Am. J. Pathol. , 1982, 109, 27). It has been shown that development of bleomycin-induced pulmonary fibrosis can be prevented by a depletion of T lymphocytes (Piguet et al, J. Exp. Med. , 1989, 170, 655), the presence of T-lymphocytes being necessary for both increased lung TNF RNA levels and the development of "fibrosis. Siliσosis, however, the other commonly used model for pulmonary fibrosis, has been shown not to be markedly affected by the absence of T-lymphocytes. .It has also been shown that administration of anti-TNF antibodies to mice during instillation of silica almost completetly prevents deposition of collagen due to silica-induced pulmonary fibrosis (P. F. Piguet et al, Nature, 1990, 344, 245). Administration of anti-TNF antibdies, however, is much less effective in the prevention of pulmonary fibrosis induced by bleomycin (P. F. Piguet et al, J. Exp. Med. , 1989, 170, 655). Thus, although much research interest has centered on the possible development of the work with T-lymphoσytes and anti-TNF antibodies, it has become clear that neither approach is likely to provide a viable method of treatment of the complete range of pulmonary fibrosis.
It is the aim of the present invention to provide a method of prophylaxis and treatment of pulmonary fibrosis. A pharmaceutical composition is sought that may be' administered both as a means of preventing the onset of pulmonary fibrosis, and treating the condition after its onset.
As mentioned earlier, it is possible that the leukocytes of the lung may have some role to play in the evolution of pulmonary fibrosis. The interactions and state of activation of leukocytes is known to be modulated by various surface proteins. One such class of surface proteins is the leukocytic integrins. There are "three leukocytic integrins, all of which are non-covalently linked heterodimers sharing a common β-subunit (CD-18) and different but homologous a-subunits: the CD-lla (or the LFA-1), the CD-lib (or Mac-1 or C 3), and the CD-llc (or the pl50, 95) (see Anderson and Springer in Ann. Rev. Med. , 1987, 38, 175).
The CD-ll/CD-18 family, also known as the leukocytic or β-2 integrins, are believed to be involved in various immune and inflammatory responses on the basis of two pieces of evidence. Firstly, CD-18 congenital deficiencies in humans lead to a severe disease, known as Leukocyte Adhesion Deficiency (LAD), which is characterised by recurrent bacterial infections, and impaired pus formation and wound healing (see Anderson and Springer in Ann. Rev. Med., 1987, 3J3, 175). LAD can be treated by bone marrow transplantation, donor rejection of HLA-mismatched bone marrow being overcome by administration of anti CD-lla mAbs to the patient from about 3 to 5 days before the graft. Secondly, the administration of anti CD-11 or anti CD-18 mAb to rodents affects the course of several immune related disorders e. g. the late administration of monoclonal antibody to LFA-1 (CD-lla) has been found to abrogate incipient murine cerebral malaria (see Grau et al, Eur. J. Immunology, 1991, 21, 2265). In the course of studies on pulmonary fibrosis, we have made the surprising discovery that pulmonary fibrosis elicited by the intratracheal instillation of either bleomycin or silica (the two commonly used pulmonary fibrosis models, as described above), can be completely prevented by the administration of anti CD-lla or anti CD-lib mAb during the period over which it is elicited. Furthermore, administration of anti CD-lla or anti CD-lib mAb has also been found to be extremely effective even after the establishment of a pulmonary fibrosis, further collagen deposition being completely prevented.
In the present invention, therefore, we provide a method of prophylaxis and treatment of pulmonary fibrosis in mammals by the administration of an effective amount of a monoclonal antibody to either or both of the leukocytic α sub-units CD-lla and CD-lib.
Normally, as experimental models, pulmonary fibrosis may be elicited by the intratracheal instillation of bleomycin or silica in mice, significant increases in the lung hydroxyproline content being observed after 15 days. However, simultaneous administration of either or both of anti CD-lla or anti CD-lib mAb during the period of instillation has been found to prevent excessive lung collagen deposition for both bleomycin and silica instillation, i. e. administration of the antibodies completely prevents the onset of both bleomycin and silica induced pulmonary fibrosis. Indeed, collagen levels in the lung, as measured by the lung hydroxyproline content, are slightly lower after administration of anti CD-11 mAbs following the instillation of silica or bleomycin, than those in normal lungs in which no fibrosis have been elicited.
As has been discussed earlier, previous attempts at preventing pulmonary fibrosis (e. g. depletion of the T-lymphocyte population), have been at least partly successful in preventing the onset of one of the experimental pulmonary fibrosis, but never both. The extraordinary success of the administration of anti CD-lla and/or anti CD-lib mAbs in preventing the onset of both types of experimental fibrosis is consequently a highly significant breakthrough. It is clear from these ' studies that administration of either or both of the anti CD-11 mAbs represents a significant method of prophylaxis of pulmonary fibrosis.
Furthermore, we have also found that administration of either or both of the anti CD-lla and anti CD-lib mAbs, after pulmonary fibrosis has already been established in mice by"the administration of bleomycin or silica, is effective in completely reversing the advance' of the fibrosis, ho further collagen deposition being observed. This is extremely surprising, since none of the previous treatments for pulmonary fibrosis shows anything approaching such a complete reversal of both bleomycin and silica induced fibrosis.
Administration of the mAbs during either prophylaxis or treatment was found to have little effect on the number of alveolar leukocytes (mainly composed of macrophages). The administration of the anti CD-11 mAbs did appear, however, to affect the function or number of the lung leukocytes. The evaluation of the lung TNF mRNA levels is in agreement with these findings: both silica and bleomycin induced fibrosis are associated with a marked rise in the F' mRNA levels, but the TNF mRNA levels were completely unaffected by administration of either anti CD-lla or anti CD-lib mAbs, which is as would be expected if there is no change in the maσrophage population. Similarly, the mRNA levels of other fibrogenic cytokines, such as IL-1, TGF-β and— PDGF, were not significantly decreased in anti CD-11 mAbs treated mice.
It is believed that the administration of anti CD-11 mAbs to humans may be of considerable benefit in the prophylaxis and treatment of a wide range of pulmonary fibrosis including idiopathiσ pulmonary fibrosis, drug-induced pulmonary fibrosis, silicosis, pneumoconiosis (e.g. asbestosis, berylliosis), and acute respiratory distress syndrome (ARDS).
In a further aspect of the present invention, we provide use of a monoclonal antibody to either or both of the leukocytic a sub-units CD-lla and CD-Ilb for the manufacture of a composition for the prophylaxis and treatment of pulmonary fibrosis in mammals.
The invention may be further illustrated by consideration of the Examples below. The animals, materials and methods used in the Examples are as follows:
Mice
CBA/Ca and C57BL/10 (BIO) mice were purchased from OLAC Ltd. (Blackthorn, UK), and bred for 3-4 generations. Experiments were performed with 2-4 month old male mice.
Bleomycin and Silica Administration
Bleomycin (Lundbeck, AVA, Copenhagen, Denmark) was dissolved in HBSS and 0.08 U in 0.1 ml was injected intra-tracheally. This procedure induced some morbidity, manifested by a loss in body weight and death by the 15th day after the injection in 5-20% of the mice. About 2 mg silica particles (DQ 12, size < 5 micron) were suspended in 0.1 ml of saline, and injected intra-tracheally. This treatment did not induce detectable loss of body weight or mortality.
Anti CD-11 mAbs
Anti CD-lla - rat anti LFA-1 IgG2b (H35.89.9), isolated as per Grau et al, Eur. J. Immunol. , 1991, 21, 2265, was used.
Anti CD-lib - rat anti CR3 IgG2b (5C6), isolated as per Rosen et al, J. Exp. Med., 1987, 166, 1685, was used.
Lung Hydroxyproline Content
This was established according to the procedure of Thrall et al, Am. J. Pathol. , 1979, 95, 117. In brief, the lungs were submitted to an acid hydrolysis and the hydrolysates were neutralsied and extracted with phenol-chloroform-isoamyl alcohol to clarify the aqueous phase. The hydroxyproline concentration was then determined colorimetrically (J. F. Woessner, Arch. Biochem. Biophys. , 1961, 93, 440).
Lung Alveolar and Interstitial Cells
The alveolae were lavaged with saline instilled within the trachea by a 25 cm hydrostatic pressure. Lung interstitial cells were isolated as described by Abraham et al, J. Immunol. , 1990, 144, 2117.
Microscopy
The lungs were fixed by the intra-tracheal administration of formol sublimate or glutaraldehyde (2% in 0.1M cacodylate buffer, pH 7.4) for paraffin or methacrylate and epon embedding respectively. Four sections from paraffin embedded material for each individual mouse were stained with hematoxilin and eosin, and a modified trichrome stain was used for the identification of platelet aggregates.
Northern Blot Analysis of TNF-a and IL-l-a mRNA
The lungs were washed in saline and frozen in liquid nitrogen. They were subsequently thawed and minced in guanidine-thiocyanate solution and the total lung RNA was isolated by guanadine/caesium chlorid centrifugation. RNAs, denatured with glyoxal, were separated on 1.2% agarose gels (4 μg per lane), and transferred onto nylon membranes. . Filters were hybridised with 32P-labelled cRNA probes (see Collart et al, J. Exp. Med., 1986, 163, 2113). Example 1
Prevention of Bleomycin or Silica Induced Collagen Deposition by CD-11 mAbs
Pulmonary fibrosis were elicited in groups of mice by the instillation of bleomycin or silica as decribed above. 500 μg of the anti CD-lla or anti CD-Ilb mAbs were injected every 5 days after instillation, and the mice were sacrificed on the 15th day after instillation. Control tests were run in which saline was injected intra-tracheally at the beginning of the experiment, and in which saline was injected into the mice at 5 day intervals instead of the antibodies after instillation by bleomycin or silica. Cells from the broncho-alveolar lavage (BAL) were recovered after an intra-tracheal instillation of saline. The lung hydroxyproline, as an evaluation of the lung collagen, was determined after lung hydrolysis. The results were as shown in Table 1 below.
Table I
Prevention of bleomycin or silica induced collagen deposition by CD-11 mAbs
Instillation Treatment BAL Lung h-proline cellxlO .-4 (μg/lung)
saline none 1.5 (1) 97 (7)
silica saline 18 (4) 144 (48) silica anti CD-lla 10 (4) 89 (30)* silica anti CD-lib 16 (3) 80 (39)*
bleomycin saline 12 (3) 131 (18) bleomycin anti CD-lla 13 (4) 88 (27)** bleomycin anti CD-lib 11 (3) 87 (16)**
Results are the mean (+sd) of the values obtained with 7-10 mice. The significance of the difference with the saline treated group was evaluated by the Mann and ithney non-parametric U test; *p < 0.02, **p < 10 -2
From these results it can be seen that in the control experiment, where saline only is instilled at the start of the test, the mean hydroxyproline content per lung was 97μg/lung. When only saline is administered to the mice after instillation of silica or bleomycin, there is a dramatic increase in the lung hydroxyproli e content by the 15th day in both cases, when compared to the control. When either anti CD-lla or anti CD-lib mAbs are administered over the 15 day period after instillation with silica or bleomycin, however, the lung hydroxyproline content is actually slightly lover than that in the control mice.
Clearly, these results are highly significant in terms of providing a method of prophylaxis for pulmonary fibrosis, given the remarkable degree to which collagen deposition in the lungs is prevented by administration of anti CD-lla or anti CD-lib mAbs.
Example 2"
Pulmonary fibrosis was elicited in mice using bleomycin or silica as in Example 1. Anti CD-lla mAbs (500 μg) were administered to the mice on day 20 and day 25 and the mice were sacrificed on day 30 after silica or bleomycin instillation. Control tests were run in which saline was injected at days 20 and 25 after instillation with silica or bleomycin instead of the mAbs. Mice, to which nothing had been administered throughout the period of the tests, were also sacrificed after 30 days. The results were as shown below in Table II. Table II
Treatment of an established fibrosis with anti CD- 11 mAb
Instillation Treatment Lung h-proline μg/lung
none none 103 (7)
silica saline 120 (22 ) silica anti CD-lla 63 ( 10 ) *
bleomycin saline 151 (37) bleomycin anti CD-lla 106 (10)**
Results are the mean (_+sd) of groups of 5 mice. Difference with the saline injected group; *p < 10 -3
**p < 10~2.
When only saline is injected after instillation of silica or bleomycin, there is a significant increase in lung hydroxyproline content by day 30, when compared to the control mice where no silica or bleomycin had been instilled, as would be expected. When anti CD-lla mAbs are administered after days 20 and 25 (i. e. after the pulmonary fibrosis have been established), it is found that in the case of bleomycin induced fibrosis, the lung hydroxyproline content is approximately the same as the value for mice in which no fibrosis have been elicited, while in the case of silica induced fibrosis, the lung hydroxyproline content is actually below that of the value obtained for mice in which no fibrosis have been elicited.
Hence, from the above it is clear that not only does the administration of anti CD 11 mAbs prevent the onset of pulmonary fibrosis if administered immediately after lung injury, it also provides a highly effective form of treatment of pulmonary fibrosis once it has already been established, effectively reversing the condition.
Example 3
Pulmonary fibrosis was elicited using silica or bleomycin in groups of 4-8 mice as described in Example 1. On day 15 the lungs were fixed by an intra-tracheal instillation of formol sublimate, and 3-4 sections across the hilus of the major lobes were prepared for each individual mouse. Sections were scored semi-quantitatively as follows:
0 = normal; 1 = about 10% of paranchyma altered; 2 = about 25%; and 3 = about 50%. Platelet microthrombi were scored per lung section, using a modified trichrome stain (see K. C..Carstairs, J. Path. Bact. , 1965, 90, 225).
Lymphoid infiltration was evaluated as the number of lymphoid foci (i.e. lymphoid formation of >20) per section.
3-4 sections from 4-8 individual mice for each group were examined. Results are a mean (_+ sd) of the score obtained for each individual mouse.
The results were as shown in table III below.
Table III
• Histological evaluation of the effect of the anti CD-lla (A) and anti CD-lib (B) mAbs
Instil- Treatment Histological Platelet Lymphoid lation score thrombi infiltration
Silica solvent 0.9 (0.6) 1.2 (1.0) 2.2 (1.4)
Silica (A) 0.7 (0.5) 0.1 (0.1) 1.2 (1.1)
Bleomycin solvent 1.3 (0.5) 1.7 (1.3) 3.6 (2.4)
Bleomycin (A) 1.2 (0.4) 0.0 0.5 (0.6)
Bleomycin (B) 0.9 (0.5) 0.0 1.1 (0.7) none solvent 0 0 0 none (A) 0 0 0

Claims

1. Use of a monoclonal antibody to either or both of the leukocytic α sub-units CD-lla and CD-lib for the manufacture of a composition for the improvement in wound repair mechanisms in mammals.
2. Use of a monoclonal antibody to either or both of the leukocytic α sub-units CD-lla and CD-lib for the manufacture of a composition for the prophylaxis and treatment of pulmonary fibrosis in mammals.
3. Use according to Claim 2, in which a monoclonal antibody to the leukocytic sub-unit CD-lla is used for the manufacture of a composition for the treatment of pulmonary fibrosis in mammals.
PCT/GB1993/000886 1992-04-28 1993-04-28 Composition for prophylaxis and treatment of pulmonary fibrosis WO1993021953A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9209177A GB2266664A (en) 1992-04-28 1992-04-28 Monoclonal antibodies for prophylaxis and treatment of pulmonary fibrosis
GB9209177.6 1992-04-28

Publications (1)

Publication Number Publication Date
WO1993021953A1 true WO1993021953A1 (en) 1993-11-11

Family

ID=10714683

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/000886 WO1993021953A1 (en) 1992-04-28 1993-04-28 Composition for prophylaxis and treatment of pulmonary fibrosis

Country Status (2)

Country Link
GB (1) GB2266664A (en)
WO (1) WO1993021953A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396530B2 (en) 2004-06-09 2008-07-08 Genentech, Inc. Method of treating granuloma annulare or sarcoid
WO2016138538A3 (en) * 2015-02-27 2016-10-20 The General Hospital Corporation Therapeutic use of integrin-binding antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMERICAN REVIEW OF RESPIRATORY DISEASE vol. 145, no. 4(2), April 1992, NEW YORK, USA page A190 P. PIGUET ET AL. 'Antibody to the leukocyte integrins CD11a or b prevent or cure pulmonary fibrosis elicited in mice by bleomycin or silica.' *
AMERICAN REVIEW OF RESPIRATORY DISEASE vol. 147, no. 2, February 1993, NEW YORK, USA pages 435 - 441 P. PIGUET ET AL. 'Effective treatment of the pulmonary fibrosis elicited in mice by bleomycin or silica with anti-CD11 antibodies.' *
BIORHEOLOGY vol. 27, no. 3-4, 1990, OXFORD, GB pages 425 - 432 J. WAUTIER ET AL. 'Leukocyte adhesion to endothelial cells.' *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396530B2 (en) 2004-06-09 2008-07-08 Genentech, Inc. Method of treating granuloma annulare or sarcoid
WO2016138538A3 (en) * 2015-02-27 2016-10-20 The General Hospital Corporation Therapeutic use of integrin-binding antibodies
US10738121B2 (en) 2015-02-27 2020-08-11 The General Hospital Corporation Therapeutic use of integrin-binding antibodies

Also Published As

Publication number Publication date
GB2266664A (en) 1993-11-10
GB9209177D0 (en) 1992-06-10

Similar Documents

Publication Publication Date Title
EP0213180B1 (en) Neovascularization inhibitors and methods for their production and use
CN1034055C (en) Method for decrease histic damage of imflammation region by monoclone antibody
Dreyer et al. Kinetics of C5a release in cardiac lymph of dogs experiencing coronary artery ischemia-reperfusion injury.
Hjort et al. Purpura Fulminans: Report of a case successfully treated with heparin and hydrocortisone Review of 50 cases from the literature
Weiss et al. Correction by factor VIII of the impaired platelet adhesion to subendothelium in von Willebrand disease
JP4819364B2 (en) Method for detecting inhibition of fibrocyte formation, and method and compound for enhancing fibrocyte formation
US4588587A (en) Method of treatment to inhibit metastasis
EP0512071B1 (en) Method and compositions for inhibiting angiogenesis
Ninnemann Immunologic defenses against infection: alterations following thermal injuries
JPH02111800A (en) Bovine xa factor and drug composition containing the same
DE3886175T2 (en) Trigramin, a polypeptide that inhibits platelet aggregation.
WO1993021953A1 (en) Composition for prophylaxis and treatment of pulmonary fibrosis
JP3558292B2 (en) Platelet adhesion inhibitor
Dalgliesh et al. Babesia argentina: disseminated intravascular coagulation in acute infections in splenectomized calves
WO1997035609A1 (en) Neovascularization inhibitor containing tissue factor pathway inhibitor
Suzuki et al. Alteration of glomerular anionic sites by the development of subepithelial deposits in experimental glomerulonephritis in the rat
JPH11180891A (en) Anti-cell death agent
Kay et al. Corneal endothelium modulation factor released by polymorphonuclear leukocytes. Partial purification and initial characterization.
Merton et al. The effect of interleukin-1 on venous endothelium–an ultrastructural study
Ohnuki Crescentic glomerulonephritis induced in the goat by immunization with homologous or heterologous glomerular basement membrane antigen
AU4348500A (en) Prevention of brain damage in stroke
EP0219400B1 (en) Glycopeptides and glycoproteins, any composition containing them, method for their preparation, and anticoagulation applications thereof
Freedman et al. The nonbacterial thrombotic vegetation
JPS6221359B2 (en)
Burkholder Glomerular disease in captive galagos

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载